Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19
UMass Chan Affiliations
Division of Hematology and Oncology, Department of MedicineDocument Type
Accepted ManuscriptPublication Date
2020-05-21Keywords
COVID-19coronavirus
convalescent plasma therapy
Fluids and Secretions
Hematology
Infectious Disease
Medical Microbiology
Therapeutics
Virus Diseases
Metadata
Show full item recordAbstract
As of May 19, 2020, there are in total 4,986,200 laboratory-confirmed Coronavirus disease-2019 (COVID-19) cases. 2% (45,425) out of 2,657,390 active COVID-19 cases are critically ill and might be requiring intensive care support. Unfortunately, even after six months since its first detection, we still do not have any definitive treatment options for COVID-19 pneumonia. Recently, the use of human convalescent plasma is being considered as a potential option for the treatment of COVID-19.Source
Sahu KK, Jindal V, Siddiqui AD, Cerny J, Gerber JM. Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19. J Med Virol. 2020 May 21. doi: 10.1002/jmv.26047. Epub ahead of print. PMID: 32437024. Link to article on publisher's site
DOI
10.1002/jmv.26047Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27569PubMed ID
32437024Related Resources
Rights
© 2020. This is a PDF file of an accepted manuscript that has been accepted for publication and posted with a 12-month embargo as allowed by the publisher’s author rights policy at https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.ae974a485f413a2113503eed53cd6c53
10.1002/jmv.26047